Literature DB >> 26110560

Oligodendroglial markers in the cuprizone model of CNS de- and remyelination.

Laura Salinas Tejedor1, Viktoria Gudi2, Valeria Kucman2, Refik Pul2, Stefan Gingele2, Kurt-Wolfram Sühs2, Martin Stangel1, Thomas Skripuletz3.   

Abstract

Oligodendrocytes are the myelinating cells of the central nervous system. Since many studies of demyelinating diseases focus their research on this cell type, there is growing interest for obtaining reliable markers that can specifically recognize oligodendroglia. Established markers are the myelin-associated neurite outgrowth inhibitor (NogoA), the transcription factor Olig2, and the antibody CC-1, the latter being directed against the protein adenomatous polyposis coli (APC). Unfortunately, it has been discussed whether APC and Olig2 could recognize astrocytes under pathological conditions as well. Hence, we performed immunohistochemical studies using the oligodendroglial markers NogoA, APC, and Olig2 in a murine model of cuprizone induced demyelination. We have found that APC co-localizes with NogoA and does not co-localize with the astrocytic marker GFAP. Olig2 shows co-localization with APC but there is also a small population of Olig2/GFAP double positive cells. Some Olig2/GFAP double positive cells are found in the corpus callosum in a narrow time window in which oligodendrocyte precursor cells proliferate in this model. In other brain regions including the cerebral cortex and hippocampus and in all regions in untreated control mice double positive Olig2/GFAP cells do not occur. In conclusion, our results underline that APC and NogoA are reliable markers for detection of mature oligodendrocytes. Olig2 is a suitable marker to stain cells of oligodendroglial origin but could be combined with GFAP to exclude the GFAP positive population of cells from the quantification of oligodendroglia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26110560     DOI: 10.14670/HH-11-640

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

1.  Investigation of Cuprizone Inactivation by Temperature.

Authors:  Sandra Heckers; Nadine Held; Jessica Kronenberg; Thomas Skripuletz; Andre Bleich; Viktoria Gudi; Martin Stangel
Journal:  Neurotox Res       Date:  2017-01-26       Impact factor: 3.911

2.  The Effect of Stereotactic Injections on Demyelination and Remyelination: a Study in the Cuprizone Model.

Authors:  Laura Salinas Tejedor; Tanja Wostradowski; Stefan Gingele; Thomas Skripuletz; Viktoria Gudi; Martin Stangel
Journal:  J Mol Neurosci       Date:  2017-01-26       Impact factor: 3.444

3.  Local injection of Lenti-Olig2 at lesion site promotes functional recovery of spinal cord injury in rats.

Authors:  Bo-Tao Tan; Long Jiang; Li Liu; Ying Yin; Ze-Ru-Xin Luo; Zai-Yun Long; Sen Li; Le-Hua Yu; Ya-Min Wu; Yuan Liu
Journal:  CNS Neurosci Ther       Date:  2017-04-27       Impact factor: 5.243

4.  Polysialylation at Early Stages of Oligodendrocyte Differentiation Promotes Myelin Repair.

Authors:  Sebastian Werneburg; Hazel L S Fuchs; Iris Albers; Hannelore Burkhardt; Viktoria Gudi; Thomas Skripuletz; Martin Stangel; Rita Gerardy-Schahn; Herbert Hildebrandt
Journal:  J Neurosci       Date:  2017-07-31       Impact factor: 6.167

5.  Astroglial and oligodendroglial markers in the cuprizone animal model for de- and remyelination.

Authors:  Maria de Los Angeles Castillo-Rodriguez; Stefan Gingele; Lara-Jasmin Schröder; Thiemo Möllenkamp; Martin Stangel; Thomas Skripuletz; Viktoria Gudi
Journal:  Histochem Cell Biol       Date:  2022-04-05       Impact factor: 2.531

Review 6.  The Cuprizone Model: Dos and Do Nots.

Authors:  Jiangshan Zhan; Teresa Mann; Sarah Joost; Newshan Behrangi; Marcus Frank; Markus Kipp
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

7.  Oligodendrocyte Lineage Marker Expression in eGFP-GFAP Transgenic Mice.

Authors:  Newshan Behrangi; Peter Lorenz; Markus Kipp
Journal:  J Mol Neurosci       Date:  2020-12-21       Impact factor: 3.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.